ENDPOINTS NEWS4h
DNA ed­it leads to ap­par­ent cure in in­fant; CDER di­rec­tor to step down; More biotechs emerge with as­sets from Chi­na; and more
Endpoints Weekly reports on iECURE's gene therapy success for OTC deficiency, FDA CDER director Patrizia Cavazzoni's departure, and Verdiva Bio's $411M launch with Sciwind assets.
FDA CDER director Patrizia Cavazzoni announces resignation
Following a string of FDA resignations, Patrizia Cavazzoni has announced that her last day will be 18 January.
BioPharma Dive22h
Patrizia Cavazzoni, key FDA official, to leave agency
The director of the FDA's main drug review office will exit on Jan. 18, according to an email sent to staff. Her departure is ...
STAT22h
Patrizia Cavazzoni, head of FDA’s drug center, to leave the agency
Patrizia Cavazzoni, leader of the FDA's Center for Drug Evaluation and Research, is leaving the agency on Jan. 18.
Becker's Hospital Review23h
FDA drug evaluation leader to exit
FDA's Center for Drug Evaluation and Research director, Patrizia Cavazzoni, MD, to step down in mid-January. Other top leaders also leaving FDA.